UB044
TargetsMicrotubule (ADC payload)
IndicationsHER2-negative breast cancer; HER2-positive gastric cancer
ClinicalI
TherapeuticsOncology
ModalitiesADC
Exclusive Summary
- Capitalize on upcoming patent cliffs in key global markets to enable "Day-1 Launch" strategies and early market entry.
- Target high-burden diseases with a gold-standard therapy, ensuring a massive and rigid patient demand globally.
- Leverage vertical integration (API + FDF) to offer superior cost competitiveness over originators and international competitors.
- Minimize regulatory risks for potential licensees through available CTD dossiers and global GMP-compliant manufacturing standards.
Asset Materials
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →